Attached files
| file | filename |
|---|---|
| EX-99.1 - Inspyr Therapeutics, Inc. | v227501_ex99-1.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 30, 2011 (June 29, 2011)
GENSPERA, INC.
(Exact name of registrant as specified in Charter)
|
Delaware
|
0001421204
|
20-0438951
|
||
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File No.)
|
(IRS Employee Identification No.)
|
2511 N Loop 1604 W, Suite 204
San Antonio, TX 78258
(Address of Principal Executive Offices)
210-479-8112
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On June 29, 2011, GenSpera, Inc. (the “Company”) announced that it had entered into a cooperation agreement with the University of Copenhagen, in Copenhagen, Denmark, to collaborate on the “SPOTLight” (Sustainable Production of Thapsigargin using Light) project. The goal of the project is to develop a metabolically engineered moss strain as a sustainable production platform for high-value plant products. Production of thapsigargin has been chosen as the first pilot project. A copy of the press release is attached to this report as Exhibit 99.01.
The information contained in this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in or exhibits to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements of Regulation FD.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 30, 2011
|
GenSpera, Inc.
|
||
|
By:
|
/s/ Craig Dionne
|
|
|
Craig Dionne
Chief Executive Officer
|
||
|
|
INDEX OF EXHIBITS
|
|
|
|
Incorporated by Reference
|
||||||||||
|
Exhibit
No.
|
Description
|
Filed
Herewith
|
Form
|
Exhibit
No.
|
File No.
|
Filing Date
|
||||||
|
99.01
|
Press Release dated June 29, 2011
|
*
|
||||||||||